These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25082788)

  • 1. Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000.
    Siegel DS
    Haematologica; 2014 Aug; 99(8):e147. PubMed ID: 25082788
    [No Abstract]   [Full Text] [Related]  

  • 2. The challenge of cross-trial comparisons using limited data.
    Laubach JP; Faber EA; Voorhees P; Moslehi J; Varga C; Niculescu L; Anderson KC; Richardson PG
    Haematologica; 2014 Aug; 99(8):e145-6. PubMed ID: 25082787
    [No Abstract]   [Full Text] [Related]  

  • 3. High dose carfilzomib proteasome inhibition induces anemia by oxidative hemolysis: A case series of 8 patients from a single centre.
    Rajagopal R; Bennett R; Liang J; Royle G
    Am J Hematol; 2019 Aug; 94(8):E215-E216. PubMed ID: 31066096
    [No Abstract]   [Full Text] [Related]  

  • 4. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.
    Siegel DS
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():2-3. PubMed ID: 25184229
    [No Abstract]   [Full Text] [Related]  

  • 5. Carfilzomib: a rare cause of posterior reversible encephalopathy syndrome.
    Katz-Agranov N; Padilla J; Scoon J; Cherian SV
    Ann Hematol; 2016 Oct; 95(11):1923-4. PubMed ID: 27477479
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiotoxicity with carfilzomib at doses greater than 27 mg/m
    Kim GY; Ahuja T; Papadopoulos J; Cirrone F
    J Oncol Pharm Pract; 2019 Jan; 25(1):229-233. PubMed ID: 28914153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
    Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K; Lonial S
    Haematologica; 2013 Nov; 98(11):1753-61. PubMed ID: 23935022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials.
    Wongsaengsak S; Kopel J; Behera TR; Chakraborty R; Ball S
    Br J Haematol; 2020 Jul; 190(2):e95-e97. PubMed ID: 32400886
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple Myeloma--Better Drugs Ask for More Stringent Evaluations.
    Sonneveld P
    JAMA Oncol; 2015 Sep; 1(6):754-5. PubMed ID: 26181637
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of Carfilzomib-Associated Cardiac Adverse Events.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
    Salvini M; Bonello F; Boccadoro M; Larocca A
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.
    Ghobrial IM; Vij R; Siegel D; Badros A; Kaufman J; Raje N; Jakubowiak A; Savona MR; Obreja M; Berdeja JG
    Clin Cancer Res; 2019 Aug; 25(16):4907-4916. PubMed ID: 31142508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Nooka AK
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on proteasome inhibitors in multiple myeloma.
    Richardson PG
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):179-81. PubMed ID: 24927266
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.